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Hayes and Jauhar’s first commentary on our review (Davies and Read 2018a) took the 
form of a blog (Hayes and Jauhar 2018). Many criticisms raised in that blog were 
later shown to be in error (Davies and Read 2018b), which presumably explains why 
they were not incorporated into their current journal commentary. Nonetheless, we 
will use this space to respond to both the blog and the journal commentary. Our 
response will clearly evidence that Hayes and Jauhar commit so many serious 
mistakes and misrepresentations (and/or misunderstandings) in both their blog and 
their commentary, that their critiques are imbalanced, imprudent and inaccurate. 
 
Search strategy and ‘biased’ selection 
In both their blog and commentary Hayes and Jauhar (2018) allege that it is ‘highly 
likely’ that our search strategy did not find all relevant studies. We are confident that 
our strategy, which not only included MEDLINE/PubMed, PsycINFO and Google 
Scholar, but previous reviews and the bibliographies of 20 relevant papers, is at least 
as thorough as most systematic reviews with regards to identifying published studies. 
We have also subsequently searched for relevant unpublished theses, dissertations and 
conference proceedings, in ProQuest and OpenGrey, and found none.   
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To support their contention that our search strategy excluded important studies, Hayes 
and Jauhar pronounce, in blog and commentary, that we failed to include the 
following five RCTs (i.e. Baldwin et a. 2004a & 2004b; Lader et al. 2004; 
Montgomery et al. 2003 & 2004). They alleged that these five trials, while primarily 
focusing on the effectiveness of antidepressants, also contained data on the 
‘incidence’ of withdrawal – that is, on how common withdrawal actually is. They 
contest that if we had included these studies our incidence rates would have been 
lower, perhaps by around 10%. As this is a core argument of their critique, we must 
inspect it carefully. 
 
Had Hayes and Jauhar read these so-called studies, even cursorily, they would have 
stopped in their tracks, as we did. Firstly, all five studies were written (either entirely 
or in part) by employees of Lundbeck Pharmaceuticals (who, in these studies, were 
researching their own drugs). Secondly, three of the five were not published as studies 
at all (so we can’t even assess their methodology). Rather they were published as 
short (300 word) research ‘supplements’ (i.e. industry-funded study-summaries that 
some journals will publish in return for an industry fee). Needless to say, the obvious 
conflicts of interests these supplements involve (Lundh et al. 2010) as well as the 
serious challenges they pose to anyone wanting to assess their methods properly 
(supplements don’t provide enough detail for that), are just two among numerous 
ethical and scientific reasons why many credible journals, such as Lancet, now refuse 
to publish them (Lancet 2010).   
 
Finally, and most damningly for Hayes and Sameer, none of the five so-called studies 
contain the incidence data they quote in their critique. To repeat, these five studies do 
not contain the very data that Hayes and Jauhar alleged we overlooked. 
  
While this, of course, explains why we did not include these studies in our systematic 
review, it does not explain why Hayes and Jauhar claimed the data were there. We 
can only surmise that they did not actually check these five studies. Rather, they took 
the shortcut of quoting a Lundbeck-funded article, published three years later (by 
Baldwin et al. 2007), which somehow ‘cites’ data from these original five studies that 
were never included in them.  
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By basing their arguments on such spurious foundations, Hayes and Jauhar not only 
demonstrate a concerning lack of caution, but also invalidate many of their core 
conclusions. For instance, they invalidate their argument that withdrawal incidence 
rates of 10-12% are not outliers. They also invalidate their re-analysis of overall 
incidence rates and their pooled figure for incidence from the RCTs (Table 1 of their 
commentary).  
 
Inclusion and exclusion criteria 
Hayes and Jauhar accurately point out (in both blog and commentary) that we did not 
register our inclusion criteria in advance. PRISMA does not require such criteria to be 
preregistered (see PRISMA guideline item #5), while we clearly state our eligibility 
criteria (which complies with PRISMA guideline item # 6. Furthermore, we address 
PRISMA items #7-#10 in the methods section). We surpassed most systematic 
reviews on depression treatments, as only around 30% (Chung et al., 2018) include 
full lists of included and excluded studies, as we do. 
 
Hayes and Jauhar then suggest (in their blog) that we should have identified the 
length of follow-up, length of antidepressant exposure, and drug-company funding as 
reasons for exclusion before undertaking the search and data extraction. Firstly, we 
went beyond both what PRISMA requests and the procedure of previous systematic 
reviews in this area, by explicitly stating in each relevant section a rationale for 
excluding each of the studies omitted. Because we did so, any diligent and impartial 
reader will clearly see that none of the three variables that Hayes and Jauhar raise 
were the sole reason for excluding any individual study at all (hence our not 
identifying them as sole reasons for exclusion before our search and data extraction). 
For example, as our tables make clear, six of the included 24 studies were identified 
as drug-company funded. Furthermore, the five drug-company studies excluded from 
our estimate of incidence, while indeed reporting artificially short durations, were 
excluded on the quite obvious ground that they failed to report incidence rates. This 
was all very plainly stated, even though Hayes and Jauhar imply otherwise. 
 
Hayes and Jauhar also take issue (in their blog) with our excluding two studies from 
our estimates of incidence “because they assessed only 9 withdrawal symptoms”. This 
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is, once again, misleading. We did not exclude them on this basis alone but, as 
explicitly stated, for a variety of methodological considerations. Both studies were 
chart-reviews, which are notoriously weak owing to reliance on practitioners being 
aware of, and recording, withdrawal reactions; while one study, oddly enough, 
excluded any withdrawal reactions commencing three days after discontinuation. 
 
We note that Hayes and Jauhar only find reasons to challenge the exclusion of studies 
with relatively low incidence rates, but do not find fault with, or even acknowledge, 
our exclusion of a study with a 97% incidence rate. 
 
Estimates of severity 
In the following statement Hayes and Jauhar make yet another error: “When 
addressing severity of withdrawal the authors only consider survey data. The reason 
given is that many of the randomised trials and naturalistic studies are short-term, or 
at risk of potential bias owing to conflicts of interest”.  
 
The confidence with which they assert this falsehood is, in our view, concerning. 
Once again, had Hayes and Jauhar carefully read these primary sources, they would 
have seen that our reasons for only considering survey data when assessing severity 
were entirely different from the ones they allege. We only considered survey data on 
severity, because the RCTs did not provide any data on the severity of withdrawal 
effects.  
 
So why do Hayes and Jauhar suggest otherwise?  Firstly, they may wrongly believe 
that the data on severity of depression pre- and post-discontinuation in Rosenbaum et 
al. (1998) is data about severity of withdrawal effects, which it is not. Secondly, the 
one RCT that did provide severity data on withdrawal (Sir et al., 2005) was, as clearly 
stipulated in our review, excluded for two reasons: because it only covered eight 
weeks treatment (which would significantly lower severity rates), and because it was 
clinician-rated rather than self-report. Hayes and Jauhar don’t acknowledge that we 
also stated that even if we had included this outlier, the weighted average of people 
who described their withdrawal effects as severe would have reduced only slightly - 
from 45.7% to 43.5%.  
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Furthermore, in their blog, Hayes and Jauhar misrepresented our 45.7% weighted 
average by wrongly stating that we had concluded that: ‘The severity of these 
symptoms is severe in over half of cases’. We should not have to point out that 45.7% 
does not constitute ‘over-half’.   
 
Assessment of study quality and concerns about surveys 
Hayes and Jauhar state in both commentary and blog that ‘This review does not 
attempt a traditional assessment of bias in the studies they include’. In fact, we 
described the methodology of every one of the 24 studies in text and tables, so that 
readers can assess for themselves their quality, including any sample biases.  
 
Hayes and Jauhar argue that it is questionable to combine data 
from randomised controlled trials and naturalistic studies with survey data (which 
makes us ask their own ‘re-analysis’ did precisely this – Figure 1). As RCTs and 
naturalistic studies are regularly covered in systematic reviews (Guyatt et al. 2008; 
Egger et al. 2001), they obviously object to our inclusion of surveys. In making this 
objection, however, Hayes and Jauhar are simply confusing a methodological 
preference for a methodological law. There is no law prohibiting the inclusion of 
experiential survey data in a systematic review. Furthermore, our ‘Limitations’ 
section clearly acknowledges both the potential minimising bias of the RCTs because 
of their artificially short treatment and follow-up durations (about which Hayes and 
Jauhar express no concern), and the potential maximising bias of the surveys because 
they may attract a disproportionate number of people unhappy with their drugs (about 
which Hayes and Jauhar express grave concern). We also pointed out, however, that 
surveys can be prone to bias either way – e.g. the largest survey contained an 
unusually high proportion (82%) of people who thought the drugs had helped them 
(Read et al. 2014), so it is feasible, in this case, that the sample bias may have been 
towards people with a generally positive attitude about antidepressants, and therefore 
the study underestimated adverse effects such as withdrawal. While the RCTs had 
extremely artificial samples and conditions (and small numbers) the large online 
surveys, while not necessarily representative of all users (like the RCTs), something 
we do acknowledge, they do represent the real-life experiences of several thousand 
people with a range of treatment durations (from weeks to years) and various speeds 
of withdrawal. Psychiatry has too often been guilty of devaluing the importance of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
experiential knowledge in its evaluation of interventions, which has in 
turn undermined our capacity to intervene effectively.  
 
In any case, how different would our incidence estimate have been had we omitted 
surveys from our analysis? The three types of studies, when grouped, did not differ 
greatly in terms of withdrawal incidence. The weighted averages are as follows: 
 
 The three surveys – 57.1% (1790/3137), 
 The five naturalistic studies – 52.5% (127/242) 
 The six RCTs – 50.7% (341/673) 
 
Reaching similar findings from different methodologies is typically seen to strengthen 
confidence in an overall, combined estimate, and not, as Hayes and Jauhar imply, 
weaken confidence. In fact, findings from the three methodology types demonstrate 
that it is broadly safe to conclude that at least half of people suffer withdrawal 
symptoms when trying to come off antidepressants. 
 
Outcome measures 
Hayes and Jauhar (in blog and commentary) rightly state that in three of the incidence 
studies that we reviewed some withdrawal symptoms (as identified by the DESS) 
were also present in some of those continuing to take antidepressants (we will explain 
to them in the ‘placebo’ section below the quite obvious reason why some studies 
may find this). However, Hayes and Jauhar wrongly claim that in the Zajecka (1998) 
study withdrawal incidence is ‘higher’ in those continuing to take antidepressants 
compared to those stopping. The difference between the two overall rates was clearly 
stated in the study as not significantly different. Furthermore, four specific withdrawal 
effects (dizziness, dysmenorrhea, rhinitis and somnolence) were significantly more 
common in participants who had come off the drugs.  
 
Hayes and Jauhar are also correct that the studies used different cut-off points on the 
Discontinuation-Emergent Signs and Symptoms Scale (DESS). We reported those 
differences faithfully in Table 1.  Furthermore, we share their concern that academic 
psychiatry has failed to focus sufficiently on changes in withdrawal symptoms rather 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
than just presence of symptoms. We disagree, however, with their speculation 
(backed by no references) that such studies, past or future, lead to ‘very small 
increases in the DESS’ and that the pharmacological contribution to withdrawal is 
therefore ‘mild and transient.’  
 
Placebo 
Hayes and Jauhar, in their commentary, are concerned that some studies find 
withdrawal symptoms in people who have been on placebos. While this was not the 
case for the majority of studies we reviewed, it was the case for one study they select 
as an example - Montgomery et al. (2005) – about which they state: the ‘DESS score 
was higher during placebo treatment than in active treatment’. Hayes and Jauhar then 
proceed to conclude, oddly enough, that such findings somehow ‘illustrate precisely 
what a nocebo effect is’ and that by allegedly missing this we ‘misunderstand simple 
principles’ about RCTs. 
  
This curious and erroneous criticism appears to be rooted in their confusion about the 
study. So, to clarify, the Montgomery study for them: after 12 weeks of open-label 
treatment, people were randomly and blindly assigned to either placebo or to 
continuation on the drug. As those randomised to placebo therefore stopped the active 
drug, this explains why many randomised to placebo suffered withdrawal effects (and 
so clearly such withdrawal does not 'illustrate' nocebo). But what can explain 
withdrawal effects being found in 9% of those who remained on the antidepressant? If 
Hayes and Jauhar imply nocebo effects can explain this, once again they are in error. 
As a careful reading of the study shows, it does not control for the fact that 
experiences classed by DESS as ‘withdrawal’ may actually be ‘treatment-emergent 
adverse events’ (as classified by TEAE). As both DESS and TEAE overlap in some 
key symptoms they classify (e.g. nausea, sweating, anxiety, dizziness, insomnia) it is 
possible that the 9% of people labelled by DESS as experiencing ‘withdrawal’ were 
rather experiencing ‘treatment-emergent adverse events’. This explains the oddity of 
so-called withdrawal occurring in the treatment group – i.e. such 'withdrawal' may not 
be withdrawal at all but an artefact of misclassifying it as such. It is strange that 
Hayes and Jauhar could overlook this quite basic point when putting together their 
commentary. 
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Combining data from different types of antidepressants 
Hayes and Jauhar (in blog and commentary) argue that different antidepressant 
medications have different withdrawal effects and that it was ‘a major conceptual 
failure to not address it in the review’. Firstly, in our systematic review we explicitly 
acknowledge that “differing half-lives affect timing of withdrawal onset”, so they are 
telling us nothing we don’t already declare. Secondly, our Table 1 (on incidence) 
actually lists rates for all the individual drugs provided by all the studies. 
Furthermore, providing global estimates was both necessary and appropriate given the 
central aim of our review. Our aim was to assess whether NICE guidelines (2009) on 
antidepressant withdrawal were evidence based, not to guide clinicians in what 
specific drugs to prescribe nor to illuminate the particularities of different 
pharmacokinetic properties. Here Hayes and Jauhar commit the all-too-common 
fallacy of criticising a study for not doing what it never set out to do. 
 
 
‘Minor errors’ 
We thank Hayes and Jauhar for identifying three very ‘minor errors’ in presentation, 
which do not impact our estimates, and which have been corrected.  
 
We are concerned, however, that they purport to identify two further ‘errors’, which 
clearly represent errors on their part not ours. Firstly, their assertion that the ‘total 
number experiencing withdrawal in the study by Sir and colleagues is 83 rather than 
110’ is wrong. They reached this figure by unjustifiably removing all withdrawal 
symptoms rated ‘minimal’, while failing to inform readers that they did so.  
 
Their second error concerns their suggestion that we misrepresented the incidence rate 
of another study (Montgomery et al. 2005) by presenting the incidence of withdrawal 
following escitalopram treatment as ‘27%, when it is 16%.’ Here Hayes and Jauhar 
again mislead the reader. The 27% rate we reported was at one week and the 16% 
they reported was at two weeks. Given we were calculating for incidence, it was 
absolutely correct for us to use the 27% figure in our calculations.  
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These are unfortunate errors for Hayes and Jauhar to make, suggesting they did not 
subject their commentary to the rigorous level of quality checking that a serious 
readership should expect. 
 
Conclusion 
For the many reasons stated above Hayes and Jauhar’s commentary turns out to be 
both inaccurate and misleading. In some cases, the critiques they offer are based on 
stark misrepresentations of study findings and/or the misreading or non-reading of 
primary sources.  
 
Furthermore, we also note that every single criticism, error and/or misrepresentation 
that Hayes and Jauhar made, resulted in the minimisation (i.e. the downplaying) of 
both the incidence and severity of antidepressant withdrawal effects. Despite their 
commentary being biased in this direction, their own re-analysis, which inexcusably 
includes studies that provide no data on incidence at all, remarkably produces an 
overall withdrawal incidence rate of 44% (Figure 1), which (despite underestimating 
the actual rate) would still represent 3.2 million adults in England alone.  
 
We accept that our overall estimates of 56% incidence, with 46% of those being 
severe, are indeed only estimates. Yet, even if the actual incidence is towards the 
lower end of the 50% to 57% range, when grouping study types, this would still 
constitute at least half of all antidepressant users (at least 3.6 million adults in 
England alone). It is crucial that amid the complexities of academic disagreement we 
do not lose sight of the scale of the problem that our systematic review helps to 
expose. 
 
In the light of this, it is also interesting to note the absence of any acknowledgment by 
Hayes and Jauhar that we are discussing a public health issue involving millions of 
people worldwide. They also fail to comment on the primary finding of the review, 
namely that national guidelines in the U.S.A. and the U.K. significantly misjudge the 
true extent of the problem. 
 
In the spirit of seeking some common ground between us, we can agree, however, 
with one statement Hayes and Jauhar made in their original blog: 
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‘It reflects negatively on the whole of the field of psychiatry that there is not 
better, clearer evidence from high quality studies on the incidence, severity and 
duration of any symptoms related to antidepressant cessation’ (Hayes and 
Jauhar 2018). 
 
Given that 16% of the English adult population was prescribed an antidepressant last 
year alone (7.3 million people), this professional oversight, and its significance, is 
hard to excuse.  
 
While better research is indeed desirable (with respect to a diversity of issues 
pertaining to withdrawal), the millions of people experiencing withdrawal effects 
cannot wait for psychiatry to determine whether they represent 50% or 57% of those 
withdrawing, or what will be the best methodologies to more precisely assess that. 
They need accurate information and proper support now. And the millions more who 
will consider starting antidepressants in the coming years are entitled, unlike those 
who have gone before, to receive accurate information about all the adverse effects 
including the difficulty they are very likely to encounter when they try to stop; 
difficulties that in many cases will be protracted and severe.  
 
A crucial step forward will be for government bodies, and professional organisations, 
to update their guidelines so as to render them evidence-based, and thereby of 
maximum benefit to the public.  
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